Opthea to Participate in the Leerink Partners Global Biopharma Conference
Opthea to Participate in the Leerink Partners Global Biopharma Conference
MELBOURNE, Australia, March 05, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT; "Opthea"), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, today announced that management will participate in one-on-one investor meetings at the Leerink Partners Global Biopharma Conference being held in Miami, Florida on March 11-13, 2024.
澳大利亚墨尔本，2024年3月5日（GLOBE NEWSWIRE）——开发治疗高度流行和进行性视网膜疾病的新疗法的临床阶段生物制药公司Opthea Limited（澳大利亚证券交易所股票代码：OPT；“Opthea”）今天宣布，管理层将参加2024年3月11日至13日在佛罗里达州迈阿密举行的Leerink Partners全球生物制药会议上的一对一投资者会议。
About Opthea
关于 Opthea
Opthea (ASX:OPT; NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to address the unmet need in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).
Opthea's lead product candidate, sozinibercept, is being evaluated in two pivotal Phase 3 clinical trials (COAST, NCT04757636, and ShORe, NCT04757610,) for use in combination with standard-of-care anti-VEGF-A monotherapies to improve overall efficacy and deliver superior vision gains compared to the standard-of-care anti-VEGF-A agents. To learn more, visit our website and follow us on X and LinkedIn.
Opthea（澳大利亚证券交易所股票代码：OPT；纳斯达克股票代码：OPT）是一家生物制药公司，正在开发新疗法，以满足在治疗高度流行和进行性视网膜疾病方面未得到满足的需求，包括湿性年龄相关性黄斑变性（湿性AMD）和糖尿病性黄斑水肿（DME）。
Opthea的主要候选产品索齐尼伯西普正在两项关键的3期临床试验（COAST，NCT04757636 和Shore，NCT04757610）中接受评估，与标准护理的抗VEGF-A单一疗法联合使用，与标准护理的抗VEGF-A药物相比，可提高整体疗效并提供卓越的视力增益。要了解更多信息，请访问我们的网站并在 X 和 LinkedIn 上关注我们。
Authorized for release to ASX by Fred Guerard, CEO
首席执行官弗雷德·盖拉德授权向澳大利亚证券交易所发行
Investor Enquiries
投资者查询
PJ Kelleher
LifeSci Advisors
Email: pkelleher@lifesciadvisors.com
Phone: 617-430-7579
PJ Kelleher
生命科学顾问
电子邮件：pkelleher@lifesciadvisors.com
电话：617-430-7579
Media
媒体
Silvana Guerci-Lena
NorthStream Global Partners
silvana@nsgpllc.com
西尔瓦娜·格尔西-莉娜
NorthStream 全球合作伙伴
silvana@nsgpllc.com
Join our email database to receive program updates:
Tel: +61 (0) 3 9826 0399
Email: info@opthea.com
加入我们的电子邮件数据库以接收计划更新：
电话：+61 (0) 3 9826 0399
电子邮件：info@opthea.com